AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03220724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 M5
Description: Administered by IM injection in the thigh
Study NCT03220724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins
Study NCT03220724 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection in the thigh
Study NCT02803749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Study NCT02803749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02358005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy 60mj
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 10 mg
Description: 10 mg CA-008 reconstituted in saline.
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 15 mg
Description: 15 mg CA-008 reconstituted in saline.
Study NCT01847794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell Search® CTC epithelial kit
Description: Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study NCT00700661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
Study NCT00700661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (unspecified)
Description: Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
Study NCT03744611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CE
Description: 550mg capsule (Eucommia ulmoides Oliver extract)
Study NCT03744611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 550mg capsule (Placebo)
Study NCT00674700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 IR house dust mites allergen extract tablet
Description: One sublingual tablet daily for one year
Study NCT00674700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 IR house dust mites allergen extract tablet
Description: One sublingual tablet daily for one year
Study NCT00674700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: One sublingual tablet daily for one year
Study NCT02049281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
Study NCT03506178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxymetazoline Nasal Spray
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline Nasal Spray
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Menthol Nasal Spray
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol Nasal Spray
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline Nasal Spray
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline Nasal Spray
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal mask with partly blocked
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT03506178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal mask with partly blocked
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study NCT01543698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study NCT01543698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study NCT01543698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study NCT02945683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reuterin D3
Description: Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
Study NCT02945683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sunflower oil, medium chain triglycerides, silicon dioxide
Study NCT02823431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel
Study NCT02823431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain aqueous gel
Study NCT00569569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: juxtascleral depot injection of Retaane
Description: juxtascleral depot injection of Retaane
Study NCT00634894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femara
Description: 2.5 mg by mouth daily x 12 weeks
Study NCT00634894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule by mouth daily x 12 weeks
Study NCT01220375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine, G-CSF, & Plerixafor
Description: Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
Study NCT01220375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Plerixafor
Description: Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
Study NCT01220375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and Plerixafor
Description: Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
Study NCT01220375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood
Description: Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
Study NCT00651794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teamwork training
Description: Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
Study NCT00651794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard NRP curriculum
Description: The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
Study NCT00651794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard NRP curriculum
Description: The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
Study NCT00651794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills practice with low-fidelity mannequin
Study NCT00651794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills practice with low-fidelity mannequin
Study NCT00651794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills practice with high-fidelity mannequin
Description: SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
Study NCT03269864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perforator flaps
Description: 40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
Study NCT04011267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy by foot-ankle segmental and functional exercises
Description: The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
Study NCT00612690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mental health consultation model program
Description: The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
Study NCT00612690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
Study NCT03548103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: Green tea extract 500 mg tid for 16 weeks
Study NCT03548103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tid for 16 weeks
Study NCT02879643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo
Description: The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
Study NCT02358005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy 120mj
Study NCT02358005 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non extracorporeal shock wave therapy
Study NCT00722722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Velcade given in four-dose cycles intravenously (through a vein).
Study NCT03939962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210 combined with FOLFOX
Description: 1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication.
Study NCT00663884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Description: mitiglinide 10mg three times a day before a meal
Study NCT00663884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: voglibose 0.2mg three times a day before a meal
Study NCT00753090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard™ Deep Dish Rotating Platform Knee
Description: Total knee replacements with the Vanguard Deep Dish Rotating Platform Knee
Study NCT00753090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard™ Cruciate Retaining Knee
Description: Total knee replacements with the Vanguard Cruciate Retaining Knee
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Knowing your Options decision aid
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Prostate Choice decision aid
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06659237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA or shotgun metagenomics
Description: 16s rRNA or shotgun metagenomics on oral and fecal samples
Study NCT00772915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly.
Study NCT00772915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described).
Study NCT04383184 — intervention group
Intervention type: PROCEDURE
Intervention: tracheoplasty
Description: tracheoplasty and only left pulmonary artery transplantation
Study NCT00211757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Description: Study drug.
Study NCT00211757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator.
Study NCT04669262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP604
Description: Administered as intravenous (IV) infusion over 30 to 60 minutes
Study NCT04669262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP593
Description: Administered as intravenous (IV) infusion over 30 to 60 minutes
Study NCT04669262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP593
Study NCT04669262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP604
Study NCT02483091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted KT intervention
Description: The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months.
Study NCT02860208 — intervention group
Intervention type: PROCEDURE
Intervention: 3 years follow-up
Description: Examination 3 years after surgical treatment of peri-implantitis
Study NCT01198210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: local peritonsillar infiltration of 2 ml saline,